SCHEMBL24349409

SCHEMBL24349409

COC(=O)NCc1nc(C)c(-c2csc(-c3ccc4[nH]nnc4c3F)n2)s1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BPGM P07738 5/20 0.66
▸ MAPT P10636 6/20 0.33
▸ SMN1; SMN2 Q16637 4/20 0.33
▸ KDM4E B2RXH2 4/20 0.33
▸ NPSR1 Q6W5P4 3/20 0.33
▸ HTT P42858 3/20 0.33
▸ LMNA P02545 2/20 0.33
▸ OPRM1 P35372 1/20 0.32
▸ ALDH1A1 P00352 4/20 0.32
▸ HPGD P15428 2/20 0.32
▸ HSD17B10 Q99714 2/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ PIK3CD O00329 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ ROCK2 O75116 1/20 0.32
▸ ROCK1 Q13464 1/20 0.32
▸ RAB9A P51151 4/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ NPC1 O15118 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24348428 0.85 BPGM (0.75) BPGMMAPTSMN1; SMN2KDM4ENPSR1
SCHEMBL24349274 0.83 BPGM (0.63) BPGMMAPTSMN1; SMN2KDM4ENPSR1
SCHEMBL24348943 0.83 BPGM (0.67) BPGMMAPTSMN1; SMN2KDM4ENPSR1
SCHEMBL24348953 0.82 BPGM (0.65) BPGMMAPTSMN1; SMN2KDM4ENPSR1
SCHEMBL24349281 0.80 BPGM (0.62) BPGMMAPTSMN1; SMN2KDM4ENPSR1
SCHEMBL24348923 0.78 BPGM (0.60) BPGMMAPTSMN1; SMN2KDM4ENPSR1
SCHEMBL24272009 0.78 BPGM (0.64) BPGMMAPTSMN1; SMN2KDM4ENPSR1
SCHEMBL24348548 0.77 BPGM (0.77) BPGMMAPTSMN1; SMN2KDM4ENPSR1
SCHEMBL24348539 0.77 BPGM (0.54) BPGMMAPTSMN1; SMN2KDM4ENPSR1
SCHEMBL24348948 0.76 BPGM (0.73) BPGMMAPTSMN1; SMN2KDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
WO-2022056449-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE BPGM, PGAM1, HBG1 BPGM 1/4885MAPT 2119/4885SMN1; SMN2 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback